← Back to patent-cliff list
CT-7439
Tier C — Watch / tradeCT-7439
Carrick Therapeutics Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK12, CDK13
Indications (approved)：Solid tumour, Ovarian cancer, Breast cancer, 尤因肉瘤, Neoplasm
Regional status
US
Phase II
2024-08-16
EU
Phase II
2024-08-16
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CT-7439?
Approved indications include: Solid tumour, Ovarian cancer, Breast cancer, 尤因肉瘤, Neoplasm.
When does the CT-7439 patent expire?
No public expiry year is available for CT-7439 yet; this page updates once verified.
How do I get a quote for CT-7439 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01